Condition-specific mobility evidence exists; formulation, diagnosis, total diet and veterinary safety review still matter.
The atlas separates a biological hypothesis, a canine or feline measurement, a controlled clinical result and a commercial longevity claim. They are not interchangeable.
What was actually measured?
Discomfort, Lameness And Joint-Severity Measures
randomized double-blind placebo-controlled clinical trialA prospective randomized double-blind placebo-controlled trial evaluated EPA and DHA in client-owned dogs with confirmed osteoarthritis.
78 enrolled client-owned dogs; 74 completed the trial · reported improvement in measured clinical signs at day 84 versus placebo
LimitationCondition-specific, short-term, formulation-specific and not a longevity outcome.
Owner-Reported Ability To Rise, Play And Walk
randomized double-blinded controlled feeding trialA separate multicenter controlled trial evaluated a high-fish-oil food in dogs with osteoarthritis.
127 client-owned dogs across 18 veterinary clinics · some functional measures improved relative to control at specified visits
LimitationA complete test diet was studied; results do not transfer automatically to every capsule or oil.
No human-to-pet conversion.
No dose is provided. Study exposure cannot be copied into an owner instruction without accounting for diet, product concentration, disease, medicines and individual risk.
“Pet supplement” is not a universal legal category.
FDA does not recognise a separate dietary-supplement category for animal products; depending on intended use, products are regulated as animal food or animal drugs. Disease-treatment or prevention claims can indicate new-animal-drug intent.
Open FDA source →Trace every material statement.
Page data version: 2026-08-18. Medical review is not claimed without a named sign-off.